Fractyl Logo Patients

Amy Schulman

Amy Schulman is a healthcare investor and managing partner of the LS Polaris Innovation Fund. She is a highly respected leader in the biotech and pharmaceutical industries. Ms. Schulman joined Polaris Partners in 2014, simultaneously assuming the role of CEO of Arsia Therapeutics, a company acquired by Eagle Pharmaceuticals in 2016. In 2015, Ms. Schulman co-founded Lyndra, where she is CEO. She became CEO and Executive Chair of Olivo Laboratories in 2017, which sold its cosmetic business to Shiseido in 2018, and serves as Executive Chair of SQZ Biotech.

Prior to joining Polaris, Schulman was the general counsel of Pfizer, president of Pfizer Nutrition, and ran Pfizer consumer healthcare after the nutrition business was sold to Nestle in 2012. She is the recipient of numerous awards including: Scientific American’s “2015 Worldview 100 List”, Fierce Biotech’s 2014 “Top 15 Women in Biotech”, and Fortune Magazine’s 2013 “50 Most Powerful Women in Business”.

Amy is a Senior Lecturer at Harvard Business School where she teaches Leadership and Corporate Accountability. She serves on the Board of Directors of Alnylam Pharmaceuticals, Ironwood Pharmaceuticals, and the Whitehead Institute.

She is a Phi Beta Kappa graduate of Wesleyan University and earned her J.D. from Yale Law School.

You are now leaving the Fractyl.com website

You are leaving Fractyl’s main website to go to Fractyl’s U.K. site.

By selecting Continue you will be directed to Fractyl’s U.K. site. If you would like to remain on Fractyl’s main site, select the Cancel button.

ContinueCancel